Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Laurie K Pearson"'
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1366-1372 (2021)
Myeloid sarcoma (MS) is a rare extramedullary manifestation of acute myelogenous leukemia (AML). The mass is composed of primitive myeloid cells that can occur in a variety of organs, most commonly the skin, lymph nodes, GI tract, bone, breast, and C
Externí odkaz:
https://doaj.org/article/b9e3c5c09ff247eeae780ac714331b9d
Autor:
Laurie K Pearson, Anita J Kumar, John B Wong, Jonathan W. Friedberg, Amy LeClair, Susan K. Parsons
Publikováno v:
Blood. 140:7917-7918
Publikováno v:
Blood. 140:12423-12424
Autor:
Renata Walewska, Ryan Jacobs, Arvind Arumainathan, Frederick Lansigan, Paul M. Barr, Christopher P. Fox, John M. Pagel, Stephen J. Schuster, Catherine C. Coombs, Laurie K Pearson, Mazyar Shadman, Chaitra S. Ujjani, Anthony R. Mato, Toby A. Eyre, Angus Broom, Bruce D. Cheson, Satyen H. Gohill, Brian T. Hill, Alan P Skarbnik, John N. Allan, Francesco Forconi, Nicole Lamanna, Lindsey E. Roeker, Danielle M. Brander, Harriet S. Walter
Publikováno v:
Br J Haematol
Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton’s tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-c
Autor:
Laurie K Pearson, Charlene C. Kabel, Paul M. Barr, Bruce D. Cheson, Chaitra S. Ujjani, Danielle M. Brander, Anthony R. Mato, Ryan Jacobs, Joanna Rhodes, Allison M. Winter, Amy A Kirkwood, Nicole Lamanna, Brian T. Hill, Alan P Skarbnik, Frederick Lansigan, John M. Pagel, Maryam Sarraf Yazdy, AnnaLynn M. Williams, Anna Schuh, Andre Goy, Hande H. Tuncer, Stephen J. Schuster, Christopher P. Fox, Colleen Dorsey, Sivraj Muralikrishnan, Mazyar Shadman, Toby A. Eyre, Arun K Singavi, John N. Allan, Nirav N. Shah, Catherine C. Coombs, Hannah Morse, Neil Bailey, Andrea Sitlinger, Chadi Nabhan, Lindsey E. Roeker
Publikováno v:
Clin Cancer Res
Purpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates
Autor:
Toby A. Eyre, John N. Allan, Allison M. Winter, Bruce D. Cheson, Hande H. Tuncer, Frederick Lansigan, Neil Bailey, Andre Goy, Paul M. Barr, Stephen J. Schuster, Danielle M. Brander, John M. Pagel, Arun K Singavi, Maryam Sarraf Yazdy, AnnaLynn M. Williams, Nirav N. Shah, Colleen Dorsey, Lindsey E. Roeker, Brian T. Hill, Alan P Skarbnik, Sivraj Muralikrishnan, Chadi Nabhan, Christopher P. Fox, Anna Schuh, Catherine C. Coombs, Mazyar Shadman, Chaitra S. Ujjani, Ryan Jacobs, Amy A Kirkwood, Andrea Sitlinger, Anthony R. Mato, Laurie K Pearson, Joanna Rhodes, Hannah Morse, Nicole Lamanna
Publikováno v:
Blood. 132:4410-4410
Introduction: Venetoclax (Ven), an oral BCL2 inhibitor, is approved for the treatment (tx) of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Ven is generally well tolerated, and side effects observed in clinical trials have been consis
Autor:
Pearson, Laurie K.1 (AUTHOR), Hamal, Ruchi2 (AUTHOR), Yu, Sanhong3 (AUTHOR), Miller, Kenneth B.1 (AUTHOR), Mensah, Felix1 (AUTHOR)
Publikováno v:
Case Reports in Oncology. 2021, Vol. 14 Issue 3, p1366-1372. 7p.